Abstract A serious complication of replacement therapy in patients with bleeding disorders is the development of 'inhibitors', particularly FVIII inhibitors in haemophilia A patients. This leads to an increase in the management cost, morbidity and mortality, especially post-operatively. The mechanism of FVIII inhibitor development is quite complex and it is difficult to predict inhibitor development, but a prompt and accurate diagnosis is critical as early therapy can save lives. The aim of this study was to screen patients with bleeding disorders in India for inhibitors, and to analyse and compare the prevalence of inhibitors in different regions in India. Patient details were recorded and blood samples were collected in sodium citrate vacutainers from 1,505 patients with bleeding disorders, in different cities in India. Coagulation and inhibitor screening assays were performed, followed by the Bethesda assay in inhibitor positive samples to quantify the FVIII inhibitor titre. Out of the 1,505 samples analysed, 1,285 were Haemophilia A patients, out of which 78 (6.07 %) were positive for 'FVIII Inhibitors'. The highest incidence of FVIII Inhibitors was seen in South India (13.04 %). The highest incidence of 20.99 % was observed in Chennai, followed by Hyderabad (13.33 %), Jammu (9.90 %) and Guwahati (8.51 %), respectively, with respect to the samples analysed. The other regions showed an inhibitor incidence \8 %. The incidence of inhibitors in haemophilia A patients is different in different regions of India; this may be due to the intensity of treatment, type of product or the genetic characteristics of these patients.
Introduction
The development of 'inhibitors' or alloantibodies against the missing coagulation factor are a serious complication of factor replacement therapy in patients with bleeding disorders. Alloantibodies that neutralize the activity of the replaced deficient factor are most common in haemophilia patients, particularly in those with severe haemophilia A. The incidence of these FVIII Inhibitors differs in different regions, as reported by several groups. It has been reported to vary from 30 % in the Japanese population, to 6.2 % in the French [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .
An earlier report has described the overall prevalence of inhibitors to be 8.2 % in patients with inherited severe haemophilia A in India [16] . Indian haemophilia patients are still more commonly treated with blood product transfusions, and factor transfusions are usually given only on an 'on-demand' basis because of the prohibitive costs involved. In case of inhibitor development, the cost of management of bleeding episodes also increases significantly with the need for expensive bypassing agents in most cases. An increased tendency of FVIII inhibitor development following surgical procedures (up to 19 %) has also been reported among Indian severe haemophilia A patients [17] .
The mechanism of FVIII Inhibitor development in congenital severe haemophilia A patients is thought to be the consequence of many different genetic and non-genetic risk factors, and not yet fully understood [18] . Accordingly, polymorphisms in immune-response associated genes i.e. IL1b, IL4, IL10, TNFA, CTLA4, and other genes, as well as HLA genotypes have been analysed along with FVIII mutations and/or polymorphisms, in relation to inhibitor development in several studies [19] [20] [21] [22] . The non-genetic risk factors that could predispose to inhibitor development include age at first treatment, type of treatment product and frequency of treatment among others [23, 24] .
Antibodies to FIX are more rarely encountered and typically seen in 1-3 % of haemophilia B patients, but about 60 % of patients who develop these inhibitors have FIX infusion-associated anaphylactic reactions [25, 26] .
The focus of this study was to analyse and compare the prevalence of inhibitors among patients with bleeding disorders in different regions in India, with a special emphasis on the prevalence of FVIII inhibitors in Indian haemophilia A patients.
Materials and Methods

Patients and Controls
Samples from 1,505 patients with bleeding disorders included in the present study were collected and sent to the Comprehensive Haemophilia Care Centre at our institute from 2011, after written consent from the patients. The study was approved by the Institutional Ethics Committee for Research on Human Subjects. A case record form (CRF) was designed to include relevant patient information such as age, sex, ethnicity, nature & site of bleeding, parental consanguinity, family history of inhibitors, details regarding FVIII infusion including type of treatment product and frequency, etc.
Methods
Sample Collection and Processing 10 cc blood was collected in 3.2 % trisodium citrate vacutainers, and centrifuged at 4,000 rpm/15 min 4°C to obtain platelet poor plasma (PPP) for various coagulation screening assays (PT, APTT, mixing Studies, Factor VIII:C, VWF: Ag, FVIII Inhibitor screening assays). Assays were carried out according to the latest recommendations/guidelines by the International Society on Thrombosis and Haemostasis (ISTH), and a uniform protocol was followed so as to have uniform diagnoses criteria in this large cohort. Those samples found to be inhibitor positive after the screening assay were confirmed and the inhibitor titres were quantitated by the Bethesda assay, and further by the Nijmegen modification (in case of low-titre inhibitors) [27] , and depending on the results, patients were classified as having high-titre or low-titre inhibitors [28] .
Results
The patients were diagnosed and classified according to the factor deficiencies. Haemophilia A (HA) was found to be most common, followed by haemophilia B (HB), von willebrand disease (VWD) and other rare factor deficiency disorders. The results have been described in Table 1 . Out of the 1505 patients, 1285 (85.38 %) had haemophilia A, 160 (10.63 %) had haemophilia B, 47 (3.12 %) had VWD, and 13 (0.86 %) had rare bleeding disorders.
The distribution of haemophilia A and haemophilia B patients with regard to disease severity has been described in Figs. 1 and 2 .
Out of the 1,285 haemophilia A patients, 1,055 (82.10 %) had severe HA with FVIII:C \ 1 %, 154 (11.98 %) had moderate HA with FVIII:C between 1 and 5 %, and 76 (5.91 %) had mild HA with FVIII:C between 6 and 50 %. Out of the 160 HB patients, 133 (83.13 %) had severe HB with FIX:C \ 1 %, 18 (11.25 %) had moderate HB with FIX:C between 1 and 5 %, and 9 (5.63 %) had mild HB with FIX:C between 6 and 50 %.
Also, out of the 1,285 haemophilia A patients, 78 (6.07 %) were found to be positive for inhibitors, all with FVIII:C \ 1 %. The FVIII inhibitor screening results have been described in Table 2 .
The highest incidence of FVIII Inhibitors i.e. 20.99 % was seen in South India i.e. Chennai, followed by Hyderabad, with an incidence of 13.33 %, and subsequently Davangere and Bangalore with incidences of 7.41 and 7.02 % respectively. Jammu showed the highest incidence of FVIII Inhibitors in North India (9.90 %), followed by Agra which showed an incidence of 5.13 %. In East India, Guwahati had an incidence of 8.51 % FVIII Inhibitors, and in West India, Mumbai had an incidence of 5.28 %, with respect to the samples analysed. The other regions showed an Inhibitor incidence \5 %.
Among the haemophilia A patients, the mean age of the inhibitor positive patients was 19.31 years (range 3-58 years) and the mean age of the inhibitor negative patients was 17.76 years (7 months-68 years). FVIII inhibitor levels ranged between 1.4 to 256 BU/ml. 37 (47.44 %) patients were found to have high-titre inhibitors [5 BU/ml, and 41 (52.56 %) patients were found to have low-titre inhibitors B5 BU/ml. Thus, the number of inhibitor positive patients with high-titre and low-titre inhibitors was nearly equal in this study. The overall FVIII Inhibitor incidence in the haemophilia A samples studied was 6.07 %, not much different from the earlier described incidence of 8.2 %. Haemarthrosis still remains the most clinically challenging bleeding manifestation in both groups of patients.
A comparative analysis of the treatment products, (either only factor concentrates/only blood products/both factor concentrates and blood products) the most important treatment-related risk factor, in the inhibitor positive and inhibitor negative patients has been described in Table 3 . With the exception of Guwahati, the difference was not statistically significant in the other regions. Among the Guwahati haemophilia A patients, those being treated with factor concentrates were inhibitor positive already (P value \0.0001****; OR 783.00; 95 % CI 13.789-44464, using the approximation of Woolf), and those being treated with a combination of both factor concentrates and blood products are inhibitor negative so far (P value \0.0001****; OR 0.001277; 95 % CI 2.249E-05-0.07252). The zonewise comparison remained significant in the East India inhibitor positive group treated with only factor concentrates (P value 0.0022**; OR 13.200; 95 % CI 3.060-56.947). Other information collected in the clinical case record form was not significantly different between the two groups and has not been described in detail.
There were no FIX Inhibitors detected in any of the haemophilia B patients. Among those with rare bleeding disorders (13 cases), Factor X (FX) deficiency was most commonly diagnosed (5 cases), followed by afibrinogenemia (2 cases), combined Factor V and FVIII deficiency (2 cases), factor II (FII) deficiency (1 case), factor V (FV) deficiency(1 case), Factor VII (FVII) deficiency (1 case), and factor XI (FXI) deficiency (1 case). There were no inhibitors detected in any of these patients with rare bleeding disorders who were screened. Many haemophilia patients were diagnosed at our centre to be actually VWD patients and were thus excluded from the FVIII/FIX inhibitor prevalence analysis. Altogether among the 527 haemophilia A patients screened, only 22 were positive for inhibitors (4.17 %). Similar is the finding in East India, wherein among the 184 HA patients screened 9 were positive i.e. 4.89 %. In North India, except Jammu which shows an incidence of 9.90 %, the prevalence of inhibitors has been found to be low in the other centres. The centres in South India have shown an increased average incidence of inhibitors compared to the other zones (East, West and North India), with Chennai having the highest incidence of nearly 21 %. It is important to note that the sample size from certain regions was too An earlier report, which largely included patients from Western India, has shown an inhibitor incidence of 8.2 % among 292 severe haemophilia A patients analysed [16] , while another report from south India describes an incidence of 13 % among 200 haemophilia patients [29] . The number of patients described in this series is much higher, but the prevalence is not significantly different from these earlier reports. A study of the FVIII haplotypes in Indian haemophilia A patients [30] has suggested that the distribution of these haplotypes (which possibly explains the higher inhibitor incidence in African-Americans because of mismatched transfusions), are not a predisposing risk factor in Indians. This could partially explain the low overall inhibitor prevalence in Indian haemophiliacs.
The results described with regard to the treatment products need to be interpreted with caution. Even though statistically significant results were observed in Guwahati, the number of inhibitor positive patients was very low i.e. only 4 patients. Similarly this is also applicable to the other regions as the number of inhibitor positive patients in each region is very low, and may not provide statistically conclusive results as yet.
When further zone-wise analysis was carried out, the difference remained significant only in the East India inhibitor positive group who were treated solely with factor concentrates. Again, the low number of patients is not enough yet to conclude that factor concentrates alone could predispose to inhibitors. Also, the South India patients who showed the highest incidence of inhibitors did not show any significant difference with regard to treatment products yet.
As the treatment-related factors can be modified if necessary, further analysis in a larger cohort of patients along with other variables may provide more information on this complex process of inhibitor development that would help in the clinical management of these patients. 
